MUMBAI / NEW DELHI, OCTOBER 15, 2026 — During early trade on Thursday, Paras Healthcare, a prominent healthcare provider backed by private equity firms Creador and 360 ONE, confirmed its Mainboard IPO launch on October 21, 2026, aiming to raise ₹1,450 crore. This public issue received regulatory clearance from SEBI on August 28, 2026, following the refiling of its Draft Red Herring Prospectus (DRHP) in June for a larger initial target of ₹1,800 crore. The company currently operates eight hospitals under the “Paras Health” brand, managing 2,211 beds across key cities.
MUMBAI / NEW DELHI, OCTOBER 28, 2026 — Ahead of Wednesday’s session, October 28, 2026, shares of hospital operator Paras Healthcare make their official stock market debut on the BSE and National Stock Exchange of India (NSE), concluding the company’s ₹1,450 Crore initial public offering that was marketed in a fixed price band of ₹660 to ₹693 per equity share.
Key Takeaways at a Glance
- Issue & Valuation Snapshot: ₹1,450 Crore total public issue, comprising a ₹500 Crore fresh issue alongside a ₹950 Crore Offer for Sale (OFS) priced at ₹660–₹693 per share.
- Timeline & Lot Economics: Equity shares list on BSE and NSE on Wednesday, October 28, 2026, following a retail bid size of 21 shares requiring a minimum outlay of ₹14,553 at the upper price band.
- Filing & Market Context: Regulatory listing approvals completed pursuant to statutory filings submitted to SEBI and official notices posted on BSE India and NSE.
Paras Healthcare Debut Timeline & Key Milestones
The primary market journey for Paras Healthcare culminates in the listing bell today. Below is the chronological schedule recorded across official stock exchange notifications:
| Event / triggers Milestone | Exact Calendar Date |
|---|---|
| Primary Issue Window & Book Building | Concluded prior to listing |
| Basis of Allotment Finalization | Concluded prior to listing |
| Official Listing on BSE & NSE | Wednesday, October 28, 2026 |
Paras Healthcare IPO Structure & Retail Lot Economics
The ₹1,450 Crore capital raise of Paras Healthcare was structured as a combination of fresh growth capital and promoter/investor secondary share divestment. Investors tracking the offering through our live IPO calendar and bidding schedule observed the final pricing fixed at the ceiling price of ₹693 per equity share.
| Issue Parameter | Verified Metric |
|---|---|
| Price Band (Per Equity Share) | ₹660 to ₹693 |
| Total Gross Issue Size | ₹1,450.00 Crore |
| Fresh Issue Component | ₹500.00 Crore (72.15 Lakh Shares) |
| Offer for Sale (OFS) Component | ₹950.00 Crore (1.37 Crore Shares) |
| Bid Lot Size | 21 Shares |
| Minimum Retail Application (1 Lot at Upper Band) | ₹14,553 |
| Listing Exchanges | BSE and NSE |
Grey Market Premium (GMP) Tracking & Debut Discovery
According to primary market intelligence reported across the IPO Grey Market Premium (GMP) tracker and tracking benchmarks such as Chittorgarh and IPOWatch, grey market sentiment ahead of the opening bell reflects pre-listing dealer expectations. In the unregulated grey market, trading activity functions as an informal gauge of market appetite, where premiums over the upper price band of ₹693 provide an indicative baseline for discovery during the pre-open session on the exchanges.
Investors should note that Grey Market Premium (GMP) data represents non-standardized street estimates derived from unofficial transactions. The actual opening print on the National Stock Exchange of India (NSE) and BSE is determined through the official exchange call auction mechanism conducted between 09:00 AM and 09:45 AM IST on listing day, factoring in broader sectoral liquidity, institutional block interest, and broader market sentiment.
Capital Breakdown: Fresh Issue vs. Offer for Sale (OFS)
Understanding the allocation between primary and secondary share issuance is essential for evaluating post-listing equity dilution:
- Fresh Issue (₹500 Crore / 72.15 Lakh Shares): A Fresh Issue represents newly minted equity shares created by the company. The net proceeds flow straight to Paras Healthcare’s balance sheet to fund operational growth, debt repayment, and capital expenditure across its regional healthcare network.
- Offer for Sale (₹950 Crore / 1.37 Crore Shares): An Offer for Sale (OFS) involves existing shareholders and early private equity investors tendering their shareholdings. The capital raised from this component goes directly to the selling shareholders, meaning it does not alter the company’s operating cash balances.
Investors who participated through the ASBA (Applications Supported by Blocked Amount) framework can recheck their share allotment details on the IPO allotment status verification hub or directly on the registrar portal prior to commencing active intraday trades.
Balanced Investor Analysis: triggers vs. Operating Risks
Market participants evaluating the hospital chain’s fundamental footing over a multi-quarter horizon should weigh clear industry tailwinds against operational considerations.
Key Operational Strengths
- Regional Healthcare Footprint: Established presence across North Indian healthcare clusters, benefiting from rising demand for multi-specialty care in non-metro urban pockets.
- Capacity Expansion Funded: The ₹500 Crore fresh capital infusion equips the management team to expand operational bed capacity and upgrade diagnostic infrastructure.
- Inpatient Volume Visibility: Consistent patient intake and increasing insurance penetration drive sustained Average Revenue Per Occupied Bed (ARPOB).
Key Downside Risks
- Capital-Intensive Operations: Hospital chains demand continuous capex investments to maintain advanced medical technologies and attract specialized clinical talent.
- Promoter & PE Divestment: The OFS component of ₹950 Crore represents a significant portion (approx. 65.5%) of the aggregate ₹1,450 Crore offering.
- Regulatory Scrutiny: Price caps on medical implants, consumable pricing regulations, and statutory compliance across municipal health standards pose ongoing margin considerations.
What to Check Before Evaluating Post-Listing Positions
- Opening Discovery vs. Issue Price: Monitor the equilibrium discovery price on the NSE/BSE pre-open relative to the ₹693 issue price.
- Institutional Trading Volume: Review bulk and block deal windows after 10:00 AM IST to identify institutional inflows or selling pressure from non-anchor holders.
- Hospital Sector Valuation Multiples: Benchmark Paras Healthcare’s trailing financial numbers and enterprise value per bed against established listed peers in the Indian healthcare space.
Frequently Asked Questions
What was the final issue price and retail lot size for Paras Healthcare?
Paras Healthcare finalized its IPO price band at ₹660 to ₹693 per equity share with a lot size of 21 shares. At the upper band of ₹693, retail bidders committed a minimum investment of ₹14,553 per application lot.
How is the ₹1,450 Crore Paras Healthcare issue proceeds divided?
The aggregate ₹1,450 Crore issue consists of a ₹500 Crore fresh issue (72.15 lakh new equity shares) directed toward company balance sheet requirements, and a ₹950 Crore Offer for Sale (1.37 crore shares) representing divestment by existing selling shareholders.
Where are Paras Healthcare shares listing today?
Shares of Paras Healthcare are scheduled for listing on both the National Stock Exchange of India (NSE) and BSE on Wednesday, October 28, 2026, accessible under designated equity ticker symbols established by the exchanges.
SEBI Compliance & Statutory Disclaimer
The information and analysis presented on IPO Bulletin (ipobulletin.com) are for informational and educational purposes only and do not constitute financial, investment, or legal advice. Securities market investments are subject to market risks; please read all offer documents (DRHP/RHP) thoroughly before committing capital. Grey Market Premium (GMP) figures are unofficial, unregulated street estimates. Always consult a SEBI-registered investment advisor before making financial decisions.
Sources referenced: The Economic Times, BSE India regulatory notices, NSE India circulars, Chittorgarh, IPOWatch.
- : /* IPO Bulletin Responsive Reading & Viewport Protection */ html, body { overflow-x: hidden !important; max-width: 100vw !important; widt…
Key Takeaways at a Glance
- Issue & Valuation Snapshot: ₹1,450 Crore total issue size, with SEBI approval received on August 28, 2026.
- Timeline & Lot Economics: IPO opens on October 21, 2026. Minimum retail investment details are pending RHP confirmation.
- Filing & Market Context: DRHP refiled on June 5, 2026, targeting an initial ₹1,800 crore, later revised to ₹1,450 crore.
Paras Healthcare IPO Dates, Issue Schedule & Allotment Timeline
The key dates for the Paras Healthcare IPO have begun to firm up, with the public issue scheduled to open next week. Investors tracking the live IPO calendar and bidding schedule should note the following confirmed and pending milestones:
| Event / Catalyst Milestone | Exact Calendar Date |
|---|---|
| DRHP Filing (initial ₹1,800 Cr) | June 5, 2026 |
| SEBI Approval Received | August 28, 2026 |
| IPO Launch Announcement | October 14, 2026 |
| IPO Open Date | October 21, 2026 |
| IPO Close Date | Pending official announcement upon RHP filing |
| Allotment Finalization | Pending official announcement upon RHP filing |
| Listing Date | Pending official announcement upon RHP filing |
Key Issue Details & Metrics for Paras Healthcare IPO
The Paras Healthcare IPO is structured as a Mainboard offering, with key financial parameters to be fully disclosed in the upcoming Red Herring Prospectus (RHP). The total issue size has been confirmed, but specific details regarding the price band and lot sizes are yet to be announced.
| Parameter | Verified Detail |
|---|---|
| Total Issue Size | ₹1,450 Crore |
| Price Band | Pending RHP confirmation |
| Face Value | Pending RHP confirmation |
| Minimum Retail Investment (1 Lot) | Pending RHP confirmation |
| Listing Exchanges | BSE & NSE |
Paras Healthcare IPO GMP Today (Grey Market Premium) & Subscription Status
As of October 15, 2026, the Grey Market Premium (GMP) data for Paras Healthcare IPO is pending initial price discovery across primary tracking platforms, including Chittorgarh and IPOWatch. The GMP, an unofficial over-the-counter indicator of investor sentiment before listing, typically emerges closer to the IPO’s opening date once the price band is announced. Investors can monitor IPO Grey Market Premium (GMP) tracker for real-time updates.
Subscription status figures for Qualified Institutional Buyers (QIB), Non-Institutional Investors (NII), and Retail Individual Investors (RII) will become available once the bidding process commences on October 21, 2026.
Paras Healthcare IPO: Issue Structure and Promoter Background
The ₹1,450 crore IPO of Paras Healthcare marks a significant event in the Indian healthcare sector. The company is backed by prominent private equity players, Creador and 360 ONE, whose involvement often signals robust growth potential and strong corporate governance. While the exact split between the fresh issue and Offer for Sale (OFS) components is yet to be detailed in the RHP, the total issue size indicates a substantial capital infusion for the company, potentially for expansion or debt reduction.
SEBI Approval and Refiled DRHP
Paras Healthcare initially filed its Draft Red Herring Prospectus (DRHP) with SEBI on June 5, 2026, aiming to raise ₹1,800 crore, as reported by Livemint and ET HealthWorld. After a thorough review, SEBI granted its approval on August 28, 2026. This approval was part of a batch that also included high-profile IPOs from Jio Platforms and Bharat PET, as highlighted by Moneycontrol and The Economic Times. The revised issue size of ₹1,450 crore suggests a recalibration of market conditions or internal capital requirements.
Operational Footprint and Expansion Plans
Paras Healthcare operates a network of eight hospitals under the “Paras Health” brand, boasting a total bed capacity of 2,211 as of June 30, 2026. These facilities are strategically located across Gurugram, Panchkula, Patna, Darbhanga, Kanpur, Udaipur, Ranchi, and Srinagar, focusing on providing comprehensive healthcare services in both metropolitan and emerging tier-2/3 cities. The company has ambitious expansion plans, including adding a 300-bed hospital in Gurugram by Fiscal 2027 and a 500-bed facility in Ludhiana. Moneycontrol previously reported in July 2026 that Paras Healthcare targets a 36% rise in bed capacity, aiming for 3,011 beds by FY28, underscoring its aggressive growth strategy.
Investment Outlook: Growth Catalysts vs. Key Risks for Paras Healthcare
Understanding the potential upside and downside is crucial for any investment decision in the primary market. For Paras Healthcare, several factors could drive its growth, while others pose significant risks.
Growth Catalysts
- Expanding Network: The company’s strategy of expanding its hospital network and bed capacity, particularly in underserved regions, positions it to capitalize on increasing healthcare demand.
- Strong PE Backing: Support from established private equity firms like Creador and 360 ONE provides financial stability, strategic guidance, and potential for future capital infusions.
- Growing Healthcare Demand: India’s growing population, rising disposable incomes, and increasing health awareness are expected to fuel demand for quality healthcare services.
Key Risk Factors
- Intense Competition: The Indian healthcare sector is highly competitive, with numerous established players and new entrants, which could impact market share and profitability.
- Regulatory Changes: The healthcare industry is subject to stringent regulations, including pricing controls, which can significantly affect revenue and operational flexibility.
- Dependence on Key Personnel: The success of healthcare providers heavily relies on attracting and retaining skilled medical professionals, a challenge in a competitive environment.
- Capital-Intensive Expansion: The company’s ambitious expansion plans require substantial capital, and any delays or cost overruns could strain its financial resources.
What to check before applying for the Paras Healthcare IPO
- Evaluate the valuation metrics, such as Price-to-Earnings (P/E) ratio, once the price band is announced, comparing it against listed peers in the healthcare sector.
- Understand the detailed utilization of the IPO proceeds, specifically how much is a fresh issue (funds going to the company) versus an Offer for Sale (funds going to selling shareholders).
- Review the promoter holding percentage both before and after the issue to assess management’s commitment and dilution.
- Thoroughly read the ‘Risk Factors’ section in the Red Herring Prospectus (RHP) to comprehend specific business, operational, and financial risks associated with Paras Healthcare.
Frequently Asked Questions
What should investors check before applying for the Paras Healthcare IPO?
Investors should thoroughly review the Red Herring Prospectus (RHP) once available, focusing on the company’s financials, valuation metrics, and the specific utilization of the IPO proceeds. Comparing its P/E ratio with listed peers and understanding the lot economics are also crucial steps before considering an application.
What is the Grey Market Premium (GMP) and expected listing sentiment for Paras Healthcare?
The Grey Market Premium (GMP) for Paras Healthcare IPO is currently pending initial price discovery across primary tracking platforms like Chittorgarh and IPOWatch. Listing sentiment will become clearer closer to the IPO launch and as GMP trends emerge, reflecting unofficial market expectations.
What are the primary balance sheet strengths and risk factors for Paras Healthcare?
Paras Healthcare’s strengths include its expanding network of hospitals and strategic focus on tier-2 and tier-3 cities, backed by significant private equity investment. Key risks involve the highly regulated and competitive nature of the healthcare industry, along with the capital-intensive requirements for its aggressive expansion plans.
SEBI Compliance & Statutory Disclaimer
The information and analysis presented on IPO Bulletin (ipobulletin.com) are for informational and educational purposes only and do not constitute financial, investment, or legal advice. Securities market investments are subject to market risks; please read all offer documents (DRHP/RHP) thoroughly before committing capital. Grey Market Premium (GMP) figures are unofficial, unregulated street estimates. Always consult a SEBI-registered investment advisor before making financial decisions.
Sources referenced: Moneycontrol, Livemint, ET HealthWorld, The Economic Times, IPO Central.
Reusing this article or its images? Credit IPO Bulletin and link to https://ipobulletin.com/2026/10/paras-healthcare-ipo-%e2%82%b91-issue-size-dates-drhp-details.html. Content licence.
💬 Reader Discussions & Insights
Only registered readers can post comments to keep discussions insightful and free of scam tips. Passwordless email login takes less than 30 seconds.
No comments yet on this analysis. Be the first reader to share your perspective!